Pharvaris NV is seeking to improve upon the standard-of-care for both treatment and prevention of hereditary angioedema (HAE) with its oral bradykinin B2 receptor antagonist deucrictibant, announcing on 5 September that it expects to launch a pivotal Phase III study by year’s end for a daily, extended-release formulation of its drug for prophylaxis. An immediate-release formulation is already in Phase III for treatment of HAE attacks.
Pharvaris Seeks To Offer New Standard Of Care In HAE
A Phase III trial with oral deucrictibant is underway for treatment of acute hereditary angioedema attacks, while the Swiss firm will begin a Phase III trial in prophylaxis later this year.
